122860-33-7

Basic information

• Product Name: 1-Cbz-4-hydroxymethylpiperidine
• Synonyms: BUTTPARK 75\50-51;BENZYL 4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE;BENZYL 4-(HYDROXYMETHYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;1-CBZ-4-HYDROXYMETHYLPIPERIDINE;1-N-CBZ-HYDROXYMETHYL-PIPERIDINE;4-HYDROXYMETHYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;N-CARBOBENZOXY-4-PIPECOLINOL;N-CARBOBENZOXY-4-PIPERIDINEMETHANOL
• CAS NO: 122860-33-7
• Molecular Formula: C₁₄H₁₉NO₃
• Molecular Weight: 249.31
• Product Categories: Alcohols and Derivatives;Amines and Anilines;pharmacetical;Piperidine
• Mol File: 122860-33-7.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 396.374 °C at 760 mmHg
• Flash Point: 193.52 °C
• Appearance: Brown Liquid
• Density: 1.163 g/cm³
• Vapor Pressure: 5.4E-07mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.94±0.10(Predicted)
• CAS DataBase Reference: 1-Cbz-4-hydroxymethylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cbz-4-hydroxymethylpiperidine(122860-33-7)
• EPA Substance Registry System: 1-Cbz-4-hydroxymethylpiperidine(122860-33-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-37/39
• Hazardous Substances Data: 122860-33-7(Hazardous Substances Data)

Usage

Uses

1-N-Cbz-hydroxymethyl-piperidine is an intermediate used in the synthesis of benzoyloxyethylpiperidinylmethylamine as fluorescent antagonists for human 5-HT4 receptors. It is also used to prepare diaminobutane derivatives as potent Ca2+-Permeable AMPA receptor antagonists.

InChI:InChI=1/C14H19NO3/c16-10-12-6-8-15(9-7-12)14(17)18-11-13-4-2-1-3-5-13/h1-5,12,16H,6-11H2

Upstream product

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 6457-49-4 4-piperidinemethanol 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 498-94-2 isonipecotic acid 
• 1885-14-9 phenyl chloroformate 
• 31139-36-3 dibenzyl dicarbonate 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 1126-09-6 4-carbethoxypiperidine 
• 160809-38-1 1-benzyl 4-ethyl piperidine-1,4-dicarboxylate 

Downstream Products

• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 159275-17-9 benzyl 4-(bromomethyl)tetrahydro-1-(2H)-pyridinecarboxylate 
• 566905-91-7 benzyl 4-{[bis(tert-butoxycarbonyl)amino]methyl}piperidine-N-carboxylate 
• 566905-99-5 2-(4-{[bis(tert-butoxycarbonyl)amino]methyl}piperidin-1-yl)ethyl 4-amino-5-chloro-2-methoxybenzoate 
• 167843-51-8 benzyl 4-((2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate 
• 160586-68-5 4-(toluene-4-sulfonyloxymethyl)piperidine-1-carboxylic acid benzyl ester 
• 178261-41-1 1-(methylsulfonyl)spiro[indoline-3,4’-piperidine] 
• 167484-18-6 benzyl spiro[indoline-3,4’-piperidine]-1‘-carboxylate 
• 184289-84-7 benzyl 1-(methylsulfonyl)spiro[indoline-3,4’-piperidine]-1‘-carboxylate 
• 180465-67-2 C₂₃H₂₉N₃O₄S 
• 180465-66-1 C₂₈H₃₇N₃O₆S 
• 159634-87-4 N-[(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-[(1,1-dimethyl-ethoxy)carbonyl]amino-2-methyl-propanamide 
• 191487-52-2 MK-677 

Relevant articles and documents

A facile synthesis of the spiroindoline-based growth hormone secretagogue, MK-677

A facile and improved route for the synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 was described. The key step adopted the Fischer indole/reduction strategy. The preparation of the key intermediates N-protected piperidine carboxaldehyde 5 and the N-Boc-O-benzyl-d-serine (2) are also optimized.

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors

The multiple roles of protein kinase D (PKD) in various cancer hallmarks have been repeatedly reported. Therefore, the search for novel PKD inhibitors and their evaluation as antitumor agents has gained considerable attention. In this work, novel pyrazolo[3,4-d]pyrimidine based pan-PKD inhibitors with structural variety at position 1 were synthesized and evaluated for biological activity. Starting from 3-IN-PP1, a known PKD inhibitor with IC50 values in the range of 94–108 nM, compound 17m was identified with an improved biochemical inhibitory activity against PKD (IC50 = 17–35 nM). Subsequent cellular assays demonstrated that 3-IN-PP1 and 17m inhibited PKD-dependent cortactin phosphorylation. Furthermore, 3-IN-PP1 displayed potent anti-proliferative activity against PANC-1 cells. Finally, a screening against different cancer cell lines demonstrated that 3-IN-PP1 is a potent and versatile antitumoral agent.

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.